Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLYS Mineralys Therapeutics, Inc.

Pre-Mkt 05-19 07:08:42 EDT

26.39

-0.99

-3.62%

盘前26.59

+0.20+0.76%

04:44 EDT

High27.55	Low26.05	Vol967.66K
Open27.50	D1 Closing27.38	Amplitude5.50%
Mkt Cap2.17B	Tradable Cap1.60B	Total Shares82.40M
T/O25.66M	T/O Rate1.60%	Tradable Shares60.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLYS","market":"US","secType":"STK","nameCN":"Mineralys Therapeutics, Inc.","latestPrice":26.39,"timestamp":1779134400000,"preClose":27.38,"halted":0,"volume":967656,"hourTrading":{"tag":"盘前","latestPrice":26.59,"preClose":26.39,"latestTime":"04:44 EDT","volume":1,"amount":26.59,"timestamp":1779180291541,"change":0.2,"changeRate":0.007579,"amplitude":0},"delay":0,"changeRate":-0.03615777940102259,"floatShares":60570600,"shares":82399500,"eps":-2.021721,"marketStatus":"Pre-Mkt","change":-0.99,"latestTime":"05-19 07:08:42 EDT","open":27.5,"high":27.55,"low":26.045,"amount":25656015.09192,"amplitude":0.054967,"askPrice":27.9,"askSize":400,"bidPrice":26,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.021721,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779197400000},"marketStatusCode":1,"adr":0,"listingDate":1676005200000,"exchange":"NASDAQ","adjPreClose":26.39,"preHourTrading":{"tag":"盘前","latestPrice":26.59,"preClose":26.39,"latestTime":"04:44 EDT","volume":1,"amount":26.59,"timestamp":1779180291541,"change":0.2,"changeRate":0.007579,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":26.5,"preClose":26.39,"latestTime":"17:44 EDT","volume":26019,"amount":686698.92,"timestamp":1779140644884,"change":0.11,"changeRate":0.004168,"amplitude":0.004168},"volumeRatio":1.0876039211186928,"impliedVol":0.7615,"impliedVolPercentile":0.308},"requestUrl":"/m/hq/s/MLYS","defaultTab":"news","newsList":[{"id":"2636006229","title":"Mineralys presents Phase 3 Launch-HTN lorundrostat data in hypertension, CKD at ESH 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636006229","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636006229?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:06","pubTimestamp":1779134819,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics flagged new Phase 3 LAUNCH-HTN trial data on lorundrostat in patients with uncontrolled hypertension and chronic kidney disease, scheduled for presentation at ESH 2026 on May 30.The oral presentation is set to highlight the drug’s efficacy profile in that population, alongside an update on tolerability and overall safety.The readout targets a high-risk subgroup that could broaden the commercial opportunity for an oral aldosterone-focused therapy in hypertension with kidney disease comorbidity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL5t3nqQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014021.USD","BK4139","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU2095319765.USD","MLYS","IE00BN0W2T93.GBP","SG9999014013.SGD","LU0314104364.USD","BK4585","IE00BKPKM429.USD","SG9999014005.SGD","BK4588","BK4112","IE00BGHQF748.EUR","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636700625","title":"Mineralys Therapeutics Announces Presentation of New Data From the Phase 3 Launch-Htn Trial of Lorundrostat at the 35TH European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636700625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636700625?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:05","pubTimestamp":1779134701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA3BXNDC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635763879","title":"Mineralys CMO David Malcom Rodman disposes of shares worth $648,330.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2635763879","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635763879?lang=en_us&edition=fundamental","pubTime":"2026-05-14 09:42","pubTimestamp":1778722959,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported sales of 22,575 common shares on May 11-13, leaving 63,443 shares owned.Sales were executed at weighted-average prices of USD 29.71, USD 29.36, USD 28.58.Filing also showed option exercises totaling 16,226 shares at prices ranging from USD 1.08 to USD 16.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL6tsGHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys CMO David Malcom Rodman disposes of shares worth $648,330.57","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633699171","title":"Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Context Therapeutics (CNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633699171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633699171?lang=en_us&edition=fundamental","pubTime":"2026-05-07 08:00","pubTimestamp":1778112051,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mineralys Therapeutics, Inc. (MLYS) and Context Ther...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-mineralys-therapeutics-inc-mlys-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-mineralys-therapeutics-inc-mlys-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSX","BK4137","LU0128526141.USD","BK4581","BK4588","BK4585","BLSG","CNTX","LABU","BK4139","LU0029874061.USD","XBI","BK4112","MLYS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633636181","title":"Mineralys Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633636181","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633636181?lang=en_us&edition=fundamental","pubTime":"2026-05-07 05:57","pubTimestamp":1778104649,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryMineralys Therapeutics Inc MLYS.OQ reported a quarterly adjusted loss of 40 cents per share for the quarter ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL8N41J3P8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633168451","title":"Earnings Flash (MLYS) Mineralys Therapeutics Posts Q1 EPS -$0.47, vs. FactSet Est of -$0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2633168451","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633168451?lang=en_us&edition=fundamental","pubTime":"2026-05-07 05:25","pubTimestamp":1778102711,"startTime":"0","endTime":"0","summary":"Earnings Flash (MLYS) Mineralys Therapeutics Posts Q1 EPS -$0.47, vs. FactSet Est of -$0.47","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633615252","title":"Mineralys Therapeutics Q1 EPS USD -0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2633615252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633615252?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:28","pubTimestamp":1778099286,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXF830D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633549661","title":"Mineralys Q1 FY26 net loss narrows to $39.3 million; G&A expenses climb to $21 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633549661","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633549661?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:14","pubTimestamp":1778098482,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics posted a net loss of $39.3 million, narrowing from $42.2 million a year earlier, while loss per share improved to $0.47 from $0.79.R&D expense fell 35.69% to $24.4 million on lower preclinical and clinical costs following conclusion of lorundrostat pivotal program in second-quarter 2025.G&A expense more than tripled to $21 million on higher professional fees and personnel-related costs, while total other income rose to $6 million from $2.2 million on higher interest earned.Cash, cash equivalents and investments edged down to $646.1 million from $656.6 million at year-end, with funding runway projected into 2028.FDA accepted NDA for lorundrostat in adults with hypertension and set a PDUFA target date of Dec. 22, 2026, with pre-commercial activities underway ahead of potential launch.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL32nC68:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2T93.GBP","BK4139","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014005.SGD","LU2210150020.SGD","BK4585","SG9999014021.USD","BK4112","NDAQ","BK4588","IE00BGHQF748.EUR","LU2210149790.SGD","LU0314104364.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633915254","title":"Mineralys Therapeutics Inc - FDA Accepts Nda for Lorundrostat in Hypertension With Pdufa Date December 22, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633915254","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633915254?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:05","pubTimestamp":1778097905,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nTUA7SPVMG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633920731","title":"BRIEF-Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633920731","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633920731?lang=en_us&edition=fundamental","pubTime":"2026-05-06 05:59","pubTimestamp":1778018380,"startTime":"0","endTime":"0","summary":"BRIEF-Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)Mineralys Therapeutics Inc MLYS.O:MINERALYS THERAPEUTICS REPORTS INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nGNX56L8xHFurther company coverage: MLYS.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUABW8HS8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633920430","title":"Mineralys grants inducement equity awards totaling 52,080 shares to two new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2633920430","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633920430?lang=en_us&edition=fundamental","pubTime":"2026-05-06 05:55","pubTimestamp":1778018124,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics granted inducement equity awards to two new non-executive employees, covering stock options for 29,760 shares plus restricted stock units for 22,320 shares.Stock options start vesting May 4, 2026, with 25% vesting on first anniversary, then 1/48 vesting monthly over four years, subject to continued service.Restricted stock units start vesting May 4, 2026, with 25% vesting on each anniversary over four years, subject to continued service.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL4VkBLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4112","BK4585","NDAQ","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014021.USD","MLYS","IE00BGHQF748.EUR","BK4139","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633910373","title":"Mineralys Therapeutics to join Bank of America Securities Health Care Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2633910373","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633910373?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:01","pubTimestamp":1777982503,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics management scheduled to participate in Bank of America Securities 2026 Health Care Conference in Las Vegas on May 11-14, 2026.Fireside chat set for Tuesday, May 12, 2026 at 9:20 a.m. PT.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL381Zmr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MLYS","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4139","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","NDAQ","SG9999014013.SGD","BK4112","SG9999014021.USD","LU2210150020.SGD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633104419","title":"Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633104419","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633104419?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:00","pubTimestamp":1777982400,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., May  05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287611/0/en/Mineralys-Therapeutics-to-Participate-in-the-Bank-of-America-Securities-Health-Care-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505439.SGD","LU0130517989.USD","LU1668664300.SGD","LU0170899867.USD","BK4207","LU1201861249.SGD","LU1366192091.USD","IE0034235188.USD","LU1718418525.SGD","LU1880398554.USD","BK4585","BAC","LU1162221912.USD","LU0128525689.USD","LU0052756011.USD","IE00BFXG1179.USD","LU1069347547.HKD","BK4504","LU0417517546.SGD","IE00BZ1G4Q59.USD","XBI","BK4007","LU0098860793.USD","LU0310800965.SGD","LU0868494617.USD","LU0208291251.USD","BK4139","LU0787776722.HKD","LU0320765646.SGD","LU0234572021.USD","LU0477156797.USD","LU1280957306.USD","LU0306806265.USD","BK4534","LU2129689514.USD","LU0234570918.USD","LU1883839398.USD","LU0130102774.USD","LU1894683264.USD","XLV","LU0971096721.USD","LU1363072403.SGD","LU0980610538.SGD","BK4581","LABU","MLYS","IE00B7SZLL34.SGD","LU0149725797.USD","LENZ","LU2129689431.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630360223","title":"Mineralys Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2630360223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630360223?lang=en_us&edition=fundamental","pubTime":"2026-04-27 18:48","pubTimestamp":1777286931,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN41A0AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630364595","title":"Mineralys Therapeutics initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2630364595","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630364595?lang=en_us&edition=fundamental","pubTime":"2026-04-27 17:40","pubTimestamp":1777282839,"startTime":"0","endTime":"0","summary":"TD Cowen initiated coverage of Mineralys Therapeutics (MLYS) with a Buy rating and no price target The company’s lorundrostat has broad, blockbuste...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mineralys-therapeutics-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mineralys-therapeutics-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4585","BK4139","BK4127","BK4566","COWN","TD","MLYS","BK4207","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629069805","title":"Mineralys CMO David Malcom Rodman disposes of USD 13,033 Mineralys shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2629069805","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629069805?lang=en_us&edition=fundamental","pubTime":"2026-04-22 07:00","pubTimestamp":1776812411,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Chief Medical Officer Rodman David Malcom sold 416 common shares on April 17, 2026 at USD 31.33.Transaction followed exercise of stock options for 416 shares at USD 15.44.He also held 4,584 stock options after transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL2CvgvL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys CMO David Malcom Rodman disposes of USD 13,033 Mineralys shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627522972","title":"Mineralys CMO David Malcom Rodman sells USD 541,129 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2627522972","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627522972?lang=en_us&edition=fundamental","pubTime":"2026-04-16 09:45","pubTimestamp":1776303959,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Chief Medical Officer David Malcom Rodman cut his stake to 69,792 shares following transactions on April 13-15.Rodman acquired 14,058 shares via option exercises on April 13 at prices ranging from USD 1.08 to USD 14.25.He sold 20,406 shares over April 13-15 at prices of USD 26.54 to USD 27.66.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL6cJXr8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627252215","title":"Mineralys CEO Jon Congleton sells 15,730 shares worth $421,988","url":"https://stock-news.laohu8.com/highlight/detail?id=2627252215","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627252215?lang=en_us&edition=fundamental","pubTime":"2026-04-16 09:45","pubTimestamp":1776303957,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics CEO Jon Congleton sold 15,730 common shares on April 13, 2026.Sale priced at USD 26.83 per share on weighted-average basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL9CvXlx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys CEO Jon Congleton sells 15,730 shares worth $421,988","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627460895","title":"Mineralys CMO David Malcom Rodman sells 2,170 shares worth $59,405","url":"https://stock-news.laohu8.com/highlight/detail?id=2627460895","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627460895?lang=en_us&edition=fundamental","pubTime":"2026-04-14 09:14","pubTimestamp":1776129264,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Chief Medical Officer Rodman David Malcom sold 2,170 shares on April 9 at USD 27.38.Transaction followed exercise of 2,170 stock options at USD 16.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL2PTPvC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys CMO David Malcom Rodman sells 2,170 shares worth $59,405","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625415489","title":"Mineralys Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2625415489","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625415489?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:48","pubTimestamp":1775652529,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics will hold its annual shareholder meeting online May 21, 2026.Shareholders will vote to elect three Class III directors for terms expiring at 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL1bXcN8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mineralystx.com;www.ir.mineralystx.com","stockEarnings":[{"period":"1week","weight":-0.1123},{"period":"1month","weight":-0.137},{"period":"3month","weight":-0.0555},{"period":"6month","weight":-0.3735},{"period":"1year","weight":0.7192},{"period":"ytd","weight":-0.2728}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.014493},{"month":2,"riseRate":0.333333,"avgChangeRate":0.081442},{"month":3,"riseRate":0.25,"avgChangeRate":0.095856},{"month":4,"riseRate":0,"avgChangeRate":-0.078413},{"month":5,"riseRate":0.75,"avgChangeRate":0.052536},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.014247},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.022154},{"month":8,"riseRate":0.666667,"avgChangeRate":0.001437},{"month":9,"riseRate":0.333333,"avgChangeRate":0.388697},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.001589},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.0429},{"month":12,"riseRate":0.333333,"avgChangeRate":0.032291}],"exchange":"NASDAQ","name":"Mineralys Therapeutics, Inc.","nameEN":"Mineralys Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mineralys Therapeutics, Inc.,MLYS,Mineralys Therapeutics, Inc.股票,Mineralys Therapeutics, Inc.股票老虎,Mineralys Therapeutics, Inc.股票老虎国际,Mineralys Therapeutics, Inc.行情,Mineralys Therapeutics, Inc.股票行情,Mineralys Therapeutics, Inc.股价,Mineralys Therapeutics, Inc.股市,Mineralys Therapeutics, Inc.股票价格,Mineralys Therapeutics, Inc.股票交易,Mineralys Therapeutics, Inc.股票购买,Mineralys Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}